Table 5.

Baseline research biomarkers in patients with and without PA

Biomarkers No PAPAP value
NMedian (Q1, Q3)NMedian (Q1, Q3)
Urinary AGT (ng/mg) 77 5.1 (3.46, 7.85) 38 8.82 (6.08, 28.3) <.0001 
Soluble VACM-1 (ng/mL) 99 978.9 (807.7, 1261.4) 55 1196.1 (961.3, 1565.8) .001 
Urinary KIM-1 (ng/mg) 67 0.50 (0.36, 0.77) 45 0.85 (0.56, 1.21) <.0001 
Urinary nephrin (ng/mg) 70 27.7 (21.1, 35.5) 33 32.4 (24.7, 40.4) .058 
Biomarkers No PAPAP value
NMedian (Q1, Q3)NMedian (Q1, Q3)
Urinary AGT (ng/mg) 77 5.1 (3.46, 7.85) 38 8.82 (6.08, 28.3) <.0001 
Soluble VACM-1 (ng/mL) 99 978.9 (807.7, 1261.4) 55 1196.1 (961.3, 1565.8) .001 
Urinary KIM-1 (ng/mg) 67 0.50 (0.36, 0.77) 45 0.85 (0.56, 1.21) <.0001 
Urinary nephrin (ng/mg) 70 27.7 (21.1, 35.5) 33 32.4 (24.7, 40.4) .058 

P values are calculated from χ2 tests or Fisher exact tests if expected cell counts were small for comparing categorical characteristics and Wilcoxon-Mann-Whitney tests for comparing continuous characteristics across strata.

Urine biomarkers (AGT, KIM-1, and nephrin) were normalized for urine creatinine.

or Create an Account

Close Modal
Close Modal